Engineering membrane proteins on interstitial cells, such as generating interleukin-2-tethered T cells to produce IL-2-positive EVs, improves anti-cancer efficacy by targeting immune checkpoints, thus enhancing the clinical applicability of immunotherapeutic agents20. The gene discussed is IL2; the disease is cancer.